Regeneron reported mid-stage data for baloncibart in POTS, describing an average 11.4-beat-per-minute reduction at the 450 mg dose along with additional updates from the broader immunotherapy landscape. In parallel, Kyverna completed its CAR-T filing, according to the same roundup. While specific regulatory timelines and efficacy endpoints were not fully detailed in the headline summary, the combination of POTS biomarker/heart-rate signals and new CAR-T regulatory progress reflects continued investor and clinical momentum across distinct modalities. The updates also highlight how companies are simultaneously pushing first-in-class antibody programs in rare cardiovascular indications while advancing next-generation cell therapies through formal submission milestones.